Anixa Biosciences (ANIX) vs Biomea Fusion (BMEA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Anixa Biosciences (ANIX) over the past year, losing 18.5% versus a loss of 34.5%. Over five years, ANIX leads with a -33.7% price change compared with -88.2% for BMEA. Anixa Biosciences is the larger company by market cap ($101.2 million vs $99.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | BMEA |
|---|---|---|
| Share price | $2.91 | $1.37 |
| Market cap | $101.16M | $99.05M |
| 1-day change | -1.36% | +3.79% |
| YTD return | -6.73% | +10.48% |
| 1-year return | -34.46% | -18.45% |
| 5-year return | -33.71% | -88.22% |
| EPS (TTM) | $-0.32 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $2.24 |
| 52-week low | $2.32 | $0.872 |
| Distance from 52-week high | -46.70% | -38.76% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +235.05% | +410.95% |
| Average volume | 302.95K | 1.47M |
| Shares outstanding | 34.76M | 72.30M |
| Employees | 4 | 37 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMEA has outperformed ANIX by 16.0 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Healthcare · Biotechnology · 4 employees
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Healthcare · Biotechnology · 37 employees
ANIX vs BMEA FAQ
Which is bigger, Anixa Biosciences or Biomea Fusion?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $101.16M compared with $99.05M for Biomea Fusion (BMEA).
Which stock has performed better over the past year, ANIX or BMEA?
BMEA returned -18.45% over the past 12 months, compared with -34.46% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Biomea Fusion in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.